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Abstract
Background Anemia and low-grade inflammation are report-
ed to be associated with impaired long-term graft outcome in
renal transplant (RTx) recipients. In this study, hemoglobin
(Hb) and inflammation marker levels were correlated with
measured glomerular filtration rate (GFR) in 128 pediatric
RTx recipients over a median follow-up period of 10 years.
Methods Serum levels of erythropoietin (EPO), hepcidin-25,
high-sensitivity C-reactive protein (CRP) (hsCRP) and
interleukin-6 (IL-6) were analyzed by enzyme-linked immu-
nosorbent assays, and GFR was analyzed by 51Cr-EDTA
clearance.
Results Themedian levels of Hb (115 g/L), hsCRP (0.4mg/L)
and IL-6 (1.4 pg/mL) and the median erythrocyte sedimenta-
tion rate (ESR; 19 mm/h) remained stable after the first post-
operative year. However, approximately half of the patients
had a normocytic, normochromic anemia, and one-third had
elevated levels of hsCRP (>1 mg/L) and ESR (>25 mm/h),
indicating continuous low-grade inflammation. Low Hb
levels preceded increased fibrosis in protocol biopsies taken
at 1.5 and 3 years after transplantation and preceded decreased
GFR by several years. Hb levels showed an inverse correla-
tion with EPO levels (r = −0.206, p = 0.038) and ESR
(r = −0.369, p < 0.001), but not with hepcidin-25, hsCRP or
IL-6 levels. The levels of the major inflammatory markers IL-
6 and hsCRP did not show a significant correlation with GFR
at either the early maintenance phase or later. In the multivar-
iable analysis, low Hb levels performed better than any other
marker with respect to predicting concomitant and subsequent
GFR.
Conclusions Anemia, but not elevated inflammatory indices,
was associated with poor concomitant and subsequent graft
function during a 10-year follow-up in pediatric RTx patients.
Keywords Anemia . Inflammation . Children . Glomerular
filtration rate . Renal transplantation
Introduction
Anemia and low-grade inflammation are common complica-
tions in renal transplant (RTx) recipients. Every second pedi-
atric RTx recipient is anemic according to the recently pub-
lished registry data of over 3600 European patients [1]. In
adults, the prevalence of post-transplantation anemia varies
around 40 % [2–4]. Both in children and adults, cross-
sectional analyses have shown an association between low
hemoglobin (Hb) levels and reduced graft function [1, 5, 6].
Similarly, low-grade inflammation, which often induces ane-
mia, has been associated with decreased patient and graft sur-
vival, especially in adults [7–9]. Thus, knowledge of the un-
derlying mechanisms is important.
The pathophysiology of anemia and inflammation in RTx
patients is believed to be multifactorial. Sufficient allograft
function is required for adequate erythropoietin (EPO) pro-
duction to maintain erythropoiesis. EPO deficiency in the ear-
ly phase after transplantation would appear to recover within
the first year post-transplantation in most patients [10–12]. At
the maintenance phase, impaired production or EPO resis-
tance may, however, account for the high prevalence of
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anemia. In general, increased inflammatory activity typically
causes EPO resistance [13–15]. Inflammatory stimulus is an
activator of the rapid production of cytokines and acute phase
proteins, such as interleukin-6 (IL-6) and C-reactive protein
(CRP). IL-6 is the main inducer of CRP production [16] and
also stimulates hepatic secretion of hepcidin-25, a peptide
which links iron availability and requirements as it regulates
iron homeostasis via the iron transporter ferroportin [17, 18].
Suppressed erythropoiesis and excess iron increases the syn-
thesis of hepcidin-25. Reduced graft function may lead to
elevated serum levels of hepcidin-25 due to reduced urinary
excretion [19].
Although anemia has been shown to be associated to de-
creased graft function, the role of low-grade inflammation and
other anemia-related risk factors on graft function remains
unexplored. The aims of this study were (1) to evaluate lon-
gitudinally the prevalence of low Hb and high levels of in-
flammatory markers at the maintenance phase (>1 year after
transplantation) in pediatric RTx patients, (2) to identify
anemia-related factors, such as blood count findings and
EPO and hepcidin-25 levels at the early maintenance phase,
when chronic allograft injury is rare and graft function is good,
(3) to analyze the association between Hb levels and the in-
flammation markers high-sensitivity CRP (hs-CRP), IL-6 and
erythrocyte sedimentation rate (ESR), (4) to study how the Hb
levels associate with the kidney biopsy findings and, especial-
ly, how the Hb and inflammation marker levels correlate with
concomitant and future glomerular filtration rate (GFR).
Materials and methods
Patients
This longitudinal analysis of post-renal transplantation Hb and
inflammation marker levels was retrospectively performed in
128 pediatric patients who were transplanted at the study cen-
ter between August 1988 and March 2006 and for whom
stored serum samples were available for extensive laboratory
analyses. All patients made regular visits to the transplant
center at 3- to 6-month intervals during the first 2 years after
renal transplantation and annually thereafter until transfer to
adult care. Data on diagnosed acute rejection or immuno-
activation in fine needle biopsies (used until 2000) during
the first year and donor age were available for 78 (61 %)
patients transplanted since 1997. Nine patients had undergone
re-transplantation. In total, 11 grafts were lost, of which nine
were lost due to chronic rejection, one due to membranous
glomerulonephritis and one due to hemolytic-uremic syn-
drome. In addition, six patients died 4–15 years after renal
transplantation.
All patients received triple-drug immunosuppression that
included a calcineurin inhibitor (cyclosporine A or
tacrolimus), an antimetabolite (azathioprine or mycopheno-
late) and low-dosemethylprednisolone, as previously reported
[20].While azathioprine + cyclosporine Awas the major com-
bination therapy in the 1990s, the use of mycophenolate +
tacrolimus increased in subsequent years. The drug combina-
tions and dosing (blood levels) were, however, individualized
according to rejection history, HLA-matching and observed
side effects. Exogenous EPO was given to three patients
(2.4 %) at 18–24 months after renal transplantation, 16 pa-
tients (14 %) at 6 years and 30 patients (35 %) at 10 years.
EPO users were excluded from the measurements of the en-
dogenous EPO levels taken at 1.5–4 years after renal
transplantation.
Laboratory data
Clinical data and annual blood parameters were retrospective-
ly obtained from the medical records. Anemia was defined
according to age and gender-adjusted reference values of Hb
for children: Hb < 112 g/L (age 1–7 years), Hb < 116 g/L (age
8–11 years), Hb < 120 g/L (age 12–15 years, girls), Hb < 124 g/L
(age 12–13 years, boys), Hb < 130 g/L (age 14–15 years, boys)
and Hb < 117 g/L in women and Hb < 134 g/L in men. Severe
anemia was defined as Hb < 100 g/L. Leucopenia and
thrombocytopenia were defined according to age-adjusted ref-
erence values as follows: leucocytes < 3.4–5 × 109/L and
thrombocytes < 150–200 × 109/L. The neutropenia level was
set to <1.0 × 109/L.
GFR was measured using 51Cr-EDTA clearance with the
modified Brochner–Mortensen equation [21, 22], and accept-
able distribution values were between 15 and 35 %. GFR was
measured on every control visit, and the annual GFR decline
(in mL/min/1.73 m2 per year) was assessed in each patient
from 1.5 years post-transplant to the last follow-up visit.
Chronic kidney disease (CKD) stages were used as follows:
stages 1–2, GFR > 60 mL/min/1.73 m2; stage 3, GFR 30–
59 mL/min/1.73 m2; stages 4–5, GFR < 30 mL/min/1.73 m2
[23].
Kidney graft biopsies
Protocol biopsies taken at 3 months after renal transplantation
were available from 31 patients with another control biopsy at
the later time point (1.5 and 3 years post renal transplantation).
Biopsies at 1.5 or 3 years after renal transplantation were
available from 50 RTx recipients. Renal histopathologic anal-
ysis was blindly performed (JL) according to the Banff ‘05
criteria [24]. The combination of interstitial fibrosis (IF) and
tubular atrophy (TA) scores (IF + TA sum score of ≤1 = IF/TA
negative; IF+ TA sum score of ≥2 = IF/TA positive) was used
to describe chronic changes in allograft histology and related
to anemia status.
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Determination of EPO and hepcidin-25 levels
The levels of EPO and hepcidin-25 were retrospectively ana-
lyzed from stored serum samples using enzyme-linked immu-
nosorbent assay (ELISA) methods (EPO: Biovendor,
Karasek, Czech Republic; hepcidin-25: DRG Instruments
GmbH, Marburg, Germany) according to the respective man-
ufacturer’s protocol. Samples for these analyses were collect-
ed as a part of the routine follow-up at various time points
between 1.5 and 4 years after renal transplantation, and these
variables were not followed longitudinally.
Determination of hsCRP and IL-6 levels
Levels of inflammatory markers hsCRP and IL-6 were deter-
mined in 747 and 764 serial serum samples, respectively. The
samples were collected from stable patients without clinical
signs of rejection or infection. HsCRP levels were measured
using commercial ELISA kits (Circulex, Nagano, Japan), and
IL-6 levels were assessed using the high-sensitivity ELISA
kits of Diaclone (Besancon, France). Cut-off values for ele-
vated hsCRP level were set to 1 and 3 mg/L, as previously
described [9].
Statistical analysis
Results are expressed as means and standard deviations for
continuous variables with a normal distribution and as me-
dians and interquartile ranges (25th to 75th percentile, IQR)
for parameters with a skewed distribution. The statistical sig-
nificance of differences between the groups was tested using
the t test or Mann–Whitney U test, Kruskall–Wallis and chi-
square tests, as appropriate. The repeated measures analysis of
variance was used for the longitudinal description of markers
over time. Pearson’s correlation coefficient and Spearman’s
rank test were used to assess the associations between vari-
ables. Abnormally distributed variables, namely, EPO,
hepcidin-25, hsCRP and IL-6, were log-transformed before
the linear regression analyses. Multivariable regression anal-
yses were performed to identify independent predictors of
continuous Hb, hsCRP and ESR levels. All variables that
correlated significantly in the univariable analysis were en-
tered into the multivariable regression models. Two-sided p-
values of <0.05 were considered to be statistically significant.
All statistical analyses were performed using SPSS version
20.0 (IBM Corp., Armonk, NY).
Results
The 128 pediatric patients enrolled in this study underwent
renal transplanation at the median age of 3.8 (IQR 1.7–9.3)
years and were followed for a median of 10 (IQR 7–14) years
(Table 1). Nearly half (48 %) of the patients were transplanted
due to congenital nephrotic syndrome of the Finnish type
(CNF) and 22 % due to congenital anomalies of the kidney
and urinary tract (CAKUT). The mean GFR of the patients
improved in the first 1.5 years after renal transplantation from
59 to 65 mL/min/1.73 m2 and decreased thereafter to 43 mL/
min/1.73 m2 at 10 years, with a mean annual GFR decline of
2.1 ± 3.7 mL/min1.73 m2 per year. Nine patients required a re-
transplantation during the follow-up period.
Anemia and blood count
The mean blood Hb level increased clearly during the first
year after transplantation and remained quite stable thereafter
with a mean value of 115 ± 15 g/L in the 1580 samples taken
at various time points between 1 and 10 years after transplan-
tation. At 1 month after renal transplantation, 87 % of the
patients were anemic, but the prevalence decreased to 48 %
at 1.5 years and varied between 40 and 57 % thereafter. CNF
patients were more anemic at 3 months (70 vs. 42 %;
p = 0.004) and 3 years (53 vs. 35 %; p = 0.043) following
renal transplantation compared to patients with other
Table 1 Characteristics of the 128 pediatric renal transplant recipients
enrolled in the study
Characteristics Values
Patients 128
Male/female 84 (66 %)/44 (34 %)
Disease leading to renal transplantation
CNF 61 (48 %)
CAKUT 28 (22 %)
Other hereditary 20 (16 %)
Inflammatory 8 (6 %)
Other 11 (9 %)
Age at transplantation, years 3.8 (1.7–9.3)
Deceased donor/living related donor 94 (73 %)/34 (27 %)
Cold ischemic time (h) 18.4 (4.2–22.3)
HLA mismatches 2.27 ± 1.14
AB mismatch 1.55 ± 0.85
DR mismatch 0.72 ± 0.55
CMV status
Seropositive donor/seronegative recipient 51 (40 %)
Duration of follow-up (years) 10 (7–14)
Graft loss 11
Deceased patients 6
Values in table are presented as the number of patients with/without the
percentage in parenthesis, as the median with the interquartile range
(IQR) in parenthesis or as the mean ± standard deviation (SD), as
appropriate
CNF, Congenital nephrotic syndrome of the Finnish type; CAKUT, con-
genital anomalies of the kidney and urinary tract; CMV, cytomegalovirus
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diagnoses. Anemia frequency during the maintenance phase
did not increase in patients who had acute rejections during
the first year. Also, donor age did not show any correlation
with Hb levels during the follow-up (data not shown). Anemia
was normocytic and normochromic in the great majority of
patients (Table 2). Leucopenia and thrombocytopenia were
more frequent in anemic patients than in non-anemic patients
[17 vs. 8 % (p < 0.001) and 14 vs. 9 % (p = 0.004), respective-
ly] (Table 2).
Anemia and graft function
Anemic patients had significantly lower simultaneous GFR
values from 6 months to 8 years after renal transplantation
than non-anemic recipients (Table 2; Fig. 1). The patients with
CKD stage 1–2 had higher Hb levels (median120 g/L) than
those with CKD stage 3 and CKD stage 4–5 (median 113 g/L
and 110 g/L, respectively; p < 0.001 for both).
Importantly, low Hb levels preceded decreased subsequent
graft function. Hb levels at 1.5–2 years after renal transplan-
tation, when the graft function was maximal, were significant-
ly related to both concomitant (r = 0.328, p < 0.001) and sub-
sequent (6 years post renal transplantation) GFR levels
(r = 0.516, p < 0.001) (Figs. 2, 3). Patients with normal Hb
showed a clear improvement in GFR after renal transplanta-
tion, reaching the mean peak level of 79 mL/min/1.73 m2
(p < 0.001) at 1.5 years, whereas patients with anemia at
>1 year after renal transplantation only reached the peak level
of 61 mL/min/1.73 m2. Thereafter, the slope of the annual
decline in GFR was comparable (1.8 vs. 2.1 mL/min/
1.73 m2; p = 0.664). The mean GFR values of children with
anemia were 6–19 mL/min/1.73 m2 lower until the end of the
10-year follow-up period. Interestingly, mean GFR decreased
to <60 mL/min/1.73 m2 at 2 years and 6 years in anemic
patients and non-anemic patients, respectively.
The influence of anemia status >1 year on annual decline
in GFR was shown by multivariable model (R2 = 0.421,
p = 0.007), where the maximal GFR at 1.5–2 years
(β = 0.567, p < 0.001) explained 27 % of the variation and
age-related anemia (β = 0.386, p = 0.002) an additional 15 %.
Anemia and biopsy findings
Protocol biopsies at 1.5 and 3 years after renal transplantation
showed IF/TA positive changes in 32 of the 50 patients
(64 %). At the time of biopsy, anemia was evident in 50 %
(16/32) of the patients with fibrosis compared to 17 % (3/18)
in those with no fibrosis (p = 0.033). The mean Hb level was
Table 2 Characteristics and comparison of variables associated with anemia
Variables All patients Normal Hb patients Anemia patients p valueb
Value n Value Abnormal (%)a n Value Abnormal (%)a n
MCV (fL) 85.9 ± 5.2 1604 85.8 ± 5.0 0.8 760 86.0 ± 5.4 1.3 843 0.330
MCH (pg/cell) 29.0 ± 2.6 1604 29.3 ± 2.9 0.7 760 28.8 ± 2.2 3.0 843 <0.001
MCHC (g/L) 337.1 ± 11.9 1601 339.9 ± 10.6 0.4 756 334.5 ± 12.5 1.5 844 <0.001
Leucocytes (109/L) 7.4 ± 2.9 1543 7.6 ± 2.7 8 717 7.2 ± 3.0 17 801 0.018
Neutrophils (109/L) 3.8 ± 2.1 999 3.9 ± 2.2 0.8 509 3.6 ± 2.0 2 466 0.012
Thrombocytes (109/L) 295.1 ± 92.2 1586 295.3 ± 79.0 9 742 295.5 ± 102.9 14 833 0.964
EPO (mIU/mL) 6.3 (4.0–10.2) 101 5.6 (4.0–8.3) 18 57 7.7 (4.5–11.5) 36 42 0.038
Hepcidin-25 (ng/mL) 9.4 (3.4–23.1) 106 8.5 (3.2–19.8) 20 56 9.6 (3.8–27.4) 31 48 0.398
HsCRP (mg/L) 0.40 (0.2–1.5) 731 0.39 (0.13–1.26) 28 351 0.43 (0.19–1.79) 36 383 0.019
IL-6 (pg/mL) 1.40 (0.2–5.0) 764 1.3 (0.1–5.8) 27 358 1.6 (0.4–4.5) 22 398 0.092
ESR (mm/h) 19 (12–30) 1512 16.0 (10–25) 23 715 22.5 (15–35) 42 783 <0.001
GFR (mL/min/1.73 m2) after renal transplantation
0.5 years 63.8 ± 19.1 115 69.6 ± 19.2 31 56 57.8 ± 17.2 79 58 <0.001
2 years 60.9 ± 18.7 71 68.2 ± 16.7 32 38 52.5 ± 17.5 73 33 <0.001
6 years 51.3 ± 15.1 105 58.1 ± 14.7 56 52 44.3 ± 12.1 89 53 <0.001
10 years 44.8 ± 14.1 72 43.5 ± 15.4 89 36 42.3 ± 12.9 94 36 0.718
Values in table are presented as the mean ± SD or the median with the IQR in parenthesis, as appropriate
Hb, Hemoglobin; MCV, mean cell volume; MCH, mean cell hemoglobin; MCHC, mean cell hemoglobin concentration; EPO, erythropoietin; HsCRP,
high-sensitivity C-reactive protein; IL-6, interleukin-6; ESR, erythrocyte sedimentation rate; GFR, glomerular filtration rate
a Prevalence of abnormal/highest quartile and GFR of <60 mL/min/1.73 m2 values
b p values for the comparison between the normal Hb and anemia groups by the t test or Mann–Whitney U test
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115 ± 12 g/L in recipients with fibrosis compared to 121
± 13 g/L in those without (p = 0.034). In 145 blood samples
drawn 0.5–2 years before the biopsy (at least 1 year after renal
transplantation), anemia was detected in 69 and 33 % of the
patients with and without fibrosis (p = 0.020), respectively,
suggesting an association between low preceding Hb levels
and increased graft fibrosis. This possible association was
further studied in a subgroup of 31 patients for whom biopsy
samples were also available at 3 months post renal transplan-
tation. Based on analysis of these blood samples, 18 of these
patients had no fibrosis at 3 months but developed it later, and
more than half (10/18) of these patients had anemia (mean Hb
Fig. 1 Box-plot of glomerular
filtration rates (GFR) at various
time points 0.5–10 years after
renal transplantation in 128
pediatric patients, with the
median value (thick horizontal
line) and lowest and the highest
quartiles (boxes) shown: a
hemoglobin (Hb), b high-
sensitivity C-reactive protein
(hsCRP), c interleukin-16 (IL-6),
d erythrocyte sedimentation rate
(ESR). Open circles Outliers,
whiskers upper and lower extreme
values, asterisk significance
(p < 0.05)
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114 g/L) at 1 year. The samples of nine patients showed no
signs of fibrosis at 1 year post transplantation, and all had
normal Hb levels (mean 133 g/L). Patients with fibrosis and
anemia at the time of the 1.5- and 3-year biopsy showed a
tendency for lower concomitant GFR (55 ± 16 mL/min/
1.73 m2) than patients with fibrosis and normal Hb (65
± 20 mL/min/1.73 m2; p = 0.132).
Erythropoietin
Serum EPO levels were somewhat higher in anemic patients
than in those with normal Hb levels (median 7.7 vs. 5.6 mIU/
mL; p = 0.038) based on analysis of 101 samples collected at
1.5–4 years after renal transplantation (Table 2). The EPO
level showed an inverse correlation with Hb concentration
(r = −0.215, p = 0.033) (Table 3; Fig. 2).Measured EPO levels
in CNF patients at 1.5–4 years after renal transplantation were
significantly lower than those in other patients (5.1 vs. 7.6;
p = 0.003) and additional EPO use was more common (48 vs.
19 %, respectively; p = 0.001). Univariable analysis showed a
positive correlation between EPO and hsCRP levels
(r = 0.248, p = 0.014), but this association did not retain sig-
nificance (β = 0.159, p = 0.146) in the multivariable model
(Table 3). EPO levels were unrelated to concurrent
(r = 0.029, p = 0.786) and subsequent (r = 0.076, p = 0.462)
GFR levels (Fig. 3).
Fig. 2 Relationship between Hb
and GFR (a), erythropoietin
(EPO; b), hepcidin-25 (c), hsCRP
(d), IL-6 (e) and ESR (f) at 1.5–
2 years after renal transplantation
(r Spearman’s rank correlation).
Hb hemoglobin; GFR glomerular
filtration rate; hsCRP high
sensitivity C-reactive protein;
ESR erythrocyte sedimentation
rate
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Hepcidin-25
Serum hepcidin-25 level was measured in 106 serum samples
drawn at 1.5–4 years after renal transplantation, with a median
value of 9.4 (IQR 3.4–23.1) ng/mL. Hepcidin-25 level was
unrelated to Hb concentration (r = −0.052, p = 0.603) (Table 3;
Fig. 2). Surprisingly, hepcidin-25 levels were inversely corre-
lated with the concomitant GFR (r = −0.305, p = 0.006) and
the values at 1.5–2 years after renal transplantation predicted
GFR at 6 years (r = −0.336, p = 0.001) (Fig. 3). In the multi-
variable model (R2 = 0.338, p = 0.005) Hb level at 1.5–2 years
post renal transplantation (β = 0.424, p < 0.001) explained
25 % of the variation in GFR level at 6 years and hepcidin-
25 level (β = −0.261, p = 0.005) explained an additional 9 %
(Fig. 3).
High-sensitivity CRP
High-sensitivity CRP levels were measured in 731 blood sam-
ples drawn at various time points between 1 month and
10 years after renal transplantation. The median hsCRP value
was 0.40 (IQR 0.16–1.48) mg/L, with no significant associa-
tionwith time since renal transplantation. In total, 31 and 13%
of the hsCRP values were >1 and >3 mg/L, respectively, in-
dicating low-grade inflammation.
Fig. 3 Relationship between
GFR at 6 years after renal
transplantation and Hb (a), EPO
(b), hepcidin-25 (c), hsCRP (d),
IL-6 (e) and ESR (f) at 1.5–
2 years after renal transplantation
(r Spearman’s rank correlation).
Hb hemoglobin; EPO
erythropoietin; ESR erythrocyte
sedimentation rate; GFR
glomerular filtration rate
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Elevated hsCRP levels were seen in 36 % of anemic versus
28 % of non-anemic patients (p = 0.038; Table 2). A weak
negative correlation between hsCRP and Hb levels was evi-
dent only in the univariable (r = −0.095, p = 0.010) analysis of
all 731 samples (Table 3), but not in samples obtained at
1.5–2 years post-RTx when the graft function was maximal
(r = −0.023, p = 0.807) (Fig. 2). HsCRP levels were compara-
ble (2.3 vs. 1.6 mg/L, p = 0.397) between patients with and
without acute rejection during the first year after renal trans-
plantation. Similarly, donor age (r = 0.102, p = 0.406) showed
no correlation with hsCRP levels. These findings were also
observed with other inflammatory markers.
HsCRP values showed only a weak correlation with kidney
graft function (Table 3). In samples taken at various time
points between 0.5 and 10 years after renal transplantation,
low hsCRP values tended to associate with higher GFR, as
shown in Fig. 1. However, after the first 0.5 years hsCRP
values were unrelated to GFR levels (Table 3). Also, the
hsCRP levels at 1.5–2 years post-RTx had no predictive value
for subsequent GFR (Fig. 3).
Interleukin-6
Serum IL-6 concentration was assessed in 764 samples, with a
median level of 1.4 (IQR 0.24–5.04) pg/mL. The levels were
significantly elevated at 1 month after renal transplantation
compared to the later period (median 3.3 vs. 1.29 pg/mL;
p = 0.004). IL-6 level showed a positive correlation with
hsCRP (r = 0.320, p < 0.001) but not with hepcidin-25
(r = 0.091, p = 0.421).
IL-6 levels were similar in the anemic and non-anemic
patients (median 1.6 vs. 1.3 pg/mL; p = 0.092) (Table 2), and
the values showed no association with the Hb levels in the
univariable analyses (Table 3; Fig. 2). Also, we found no
correlation between the IL-6 levels with the concomitant or
subsequent GFR values at any time point (Figs. 1, 3).
Erythrocyte sedimentation rate
The ESR was recorded in 1512 blood samples, with a median
level of 19.0 (IQR 12–30) mm/h. Elevated ESR (>25 mm/h)
was seen in 33 % of the samples throughout the follow-up,
and ERS levels showed a positive correlation with hsCRP
values (r = 0.320, p < 0.001) (Table 3). The median ESR value
was 22.5 mm/h in the anemic and 16.0 mm/h in the non-
anemic patients (p < 0.001, Table 2). ESR values also showed
a strong negative correlation with Hb levels at 1.5–2 years
after renal transplantation (r = −0.383, p < 0.001) and in
univariable and multivariable analyses of samples from differ-
ent time points (β = −0.369, p < 0.001) (Table 3).
As shown in Fig. 1, patients with high ESR showed a lower
GFR during the follow-up, but this was statistically significant
(p < 0.05) only at 1 year after renal transplantation. ESR levels
at 1.5–2 years after renal transplantation showed a negative
correlation (r = − 0.276, p = 0.005) with the GFR levels at
6 years in the univariable analysis (Fig. 3), but the predictive
value of ESR on GFR level was no longer significant in the
multivariable analysis. The ESR levels increased along the
CKD stages, from 21 mm/h in the patients with CKD stage
1–2 to 23 mm/h and 27 mm/h in those with CKD stage 3 and
CKD stage 4–5, respectively (p = 0.003).
Combining markers of anemia and inflammation
Patients with simultaneously elevated ESR of >25 mm/h and
hsCRP of >1 mg/L showed decreased concurrent GFR at
0.5 years after renal transplantation when compared to those
who did not (50.4 vs. 69.4 mL/min/1.73 m2; p = 0.001). This
was not seen at other time points. Moreover, GFR levels in
patients with simultaneously elevated hsCRP and IL-6 levels
did not differ from those in other patients.
Combined anemia and high ESR level at 1.5–2 years after
renal transplantation was associated with decreased concomi-
tant and subsequent GFR up to 8 years after renal transplan-
tation (p < 0.05 for all). However, anemia status (β = −0.401,
p < 0.001) explained 19 % of the variation in GFR at 6 years
and elevated ESR level (β = −0.147, p = 0.107) explained on-
ly an additional 2% (R2 = 0.211, p = 0.107). A similar analysis
of combined anemia and elevated hsCRP or IL-6 level showed
an insignificant effect of elevated inflammatory indices on
GFR.
Discussion
We found low Hb and elevated inflammatory marker levels in
a substantial proportion of pediatric Rtx patients throughout
the 10-year post-operative follow-up. Hb levels showed an
inverse correlation with EPO and ESR values but not with
hepcidin-25, IL-6 or hsCRP levels. Hb levels also showed a
strong inverse correlation with the measured GFR values, and
anemia predicted reduced long-term graft function in these
patients. In contrast, the inflammatory markers correlated
poorly with the concurrent and future GFR values and did
not bring additional diagnostic value to the Hb measurements.
These results suggest that anemia, but not low-grade inflam-
mation, is associated with impaired graft function in pediatric
RTx patients.
We found an anemia frequency of 87 % during the early
months after renal transplantation, decreasing to 40–56% dur-
ing the subsequent 1–10 years. This result is in line with pre-
vious reports both in adult and pediatric RTx patients, espe-
cially during the first months after the operation [1, 25, 26]. In
the study of Yorgin et al. [27] on 162 pediatric RTx patients,
the peak anemia (hematocrit) prevalence (84 %) was observed
1 month after RTx, with the percentage remaining high
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(64–82 %) during the 5-year follow-up. In that study, early
anemia was less frequent in patients younger than 2 years at
renal transplantation in comparison with older children. In our
cohort, the youngest children were more anemic, which may
be due to the high prevalence (76 %) of young CNF patients
who were more anemic at the early phase and also later on.
Also, the measured EPO levels at 1.5–4 years after renal trans-
plantation were significantly lower among CNF patients and
additional EPO use was more common, possibly reflecting the
effect of bilateral nephrectomy prior to renal transplantation.
The differences between CNF and other patients is, however,
difficult to explain over the long term because long-term graft
function is comparable in CNF and other patients [20]. Also,
the basic defect in CNF, namely, lack of the podocyte protein
nephrin, should not predispose these children to anemia.
An important but yet unresolved question is what causes
anemia in RTx patients [28, 29]. We found leucopenia and
thrombocytopenia in only a small proportion of the anemic
patients (17 and 14 %, respectively), suggesting that general-
ized bone marrow suppression may be the cause in some, but
not in the majority, of the patients. Iron deficiency may lead to
anemia and has been reported in over 30 % of pediatric RTx
patients [27, 30]. In our cohort, only 1–3 % of the anemic
patients had microcytosis or hypochromia. In a subgroup anal-
ysis of 39 patients, only two patients had simultaneous ane-
mia, microcytosis and low transferrin saturation (data not
shown). Also, hepcidin-25 levels were not decreased in our
anemic patients, suggesting that iron deficiency is the cause of
anemia in only a minority of patients. This fits to our clinical
experience that iron therapy is quite rarely helpful in anemic
RTx patients.
Low-grade inflammation is a clinical challenge during the
post-transplant period and may induce anemia [17, 31]. We
analyzed the association of the inflammatory markers IL-6,
hsCRP and ESR with the Hb levels during the 10-year fol-
low-up and especially at the early maintenance phase when
graft function was still good inmost patients. The results show
that IL-6 and hsCRP values did not correlate with Hb levels
and that the values were similar in anemic and non-anemic
patients, speaking against a strong association between in-
flammatory processes and anemia. On the other hand, ESR
values correlated negatively with the Hb levels, and anemic
patients had higher ESR values. Little is known about the
behavior of ESR after transplantation, but the data on CKD
and dialysis patients suggest that the ESR values are affected
by several factors, such as plasma fibrinogen, ferritin, platelet
and white cell counts as well as hematocrit [32].
The interesting question which remains to be answered is:
Which comes first—anemia or kidney graft injury? Fibrosis
may impair the production of EPO by the peritubular cells,
leading to anemia [33], which fits with our finding of an as-
sociation between Hb levels and IF/TA findings in the proto-
col biopsy samples. On the other hand, it is known that lowHb
levels may associate with tissue hypoxia, possibly accelerat-
ing the development of chronic allograft injury [34–37]. The
importance of graft function was shown in a multicenter study
by Choukroun et al. who demonstrated that normalization of
Hb levels by exogenous EPO slowed down the decrease of
GFR levels and reduced the incidence of end-stage renal dis-
ease in adult RTx patients [38]. In our study, anemia seemed to
appear before renal fibrosis (1.5- and 3-year protocol biop-
sies), as 56 % of the RTx patients who developed fibrosis after
the 3-month biopsy were anemic at 1 year post surgery com-
pared to none among those patients with no fibrosis at any
biopsy (p = 0.009).
Our anemic patients showed up to a 23 % decrease in the
measured GFR at each time point during the 10-year follow-
up, thereby verifying the previous cross-sectional observa-
tions on the association between the poor graft function and
low Hb levels [1, 5, 27, 39, 40]. EPO is the main regulator of
erythropoiesis, and anemia may be attributed to insufficient
EPO production by the failing graft. However, the frequency
of anemia did not increase with time and, at the early mainte-
nance phase, EPO levels were higher, not lower, in anemic
patients. Consistent with our results, serum EPO levels were
inversely associated with Hb levels, but unrelated to GFR
levels in a study conducted by Sinnamon and co-workers
[41]. Adult RTx patients with anemia have been shown to
present an additional 25 % risk for renal graft loss [42], and
increased risk for mortality [6, 26, 43]. The small number of
graft losses among the patients in our study did not allow us to
analyze the impact of low Hb levels on terminal graft failure.
Low Hb levels predicted reduced graft function by several
years in our patients. Somewhat surprisingly, the inflammato-
ry markers IL-6, hsCRP and ESR did not correlate with con-
current or future graft function. Also, no benefit was acquired
by combining the marker findings. A marginal association
was, however, found between the hepcidin-25 and subsequent
GFR levels (p = 0.006). In adult RTx patients, low-grade in-
flammation has been associated with increased mortality,
caused by increased occurrence of cardiovascular complica-
tions [7]. In pediatric patients these events are extremely rare
and were not observed in our cohort.
The strengths of our study were its longitudinal study de-
sign, extensive follow-up of Hb and inflammatory marker
concentrations as well as annual GFR assessment by 51Cr-
EDTA clearance for up to 10 years after renal transplantation.
Our study also has a number of limitations, including the
retrospective data collection and the single measurement of
EPO and hepcidin-25 levels, which limit the conclusions on
causality. Also, it was not possible to study the impact of
different immunosuppressive drugs as the immunosuppres-
sive protocol, including low-dose methylprednisolone, cal-
cineurin inhibitors (cyclosporine A or tacrolimus) and anti-
metabolite (azathioprine or mycophenolate), was individual-
ized and changed over time, excluding a meaningful analysis.
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However, the increase in the use of tacrolimus + mycopheno-
late combination therapy in recent years, compared to the
1990s when azathioprine + cyclosporine A was the major
combination therapy, has not resulted in any change in the
frequency of anemia or elevated inflammatory markers (data
not shown).
In conclusion, our study confirms previous cross-sectional
findings that anemia is common among pediatric RTx patients
years after the operation. The Hb levels correlated negatively
with the concomitant and future graft function. In contrast,
inflammatory markers hsCRP and IL-6 did not associate with
Hb levels or GFR. A better understanding of the pathophysi-
ology of anemia-associated deterioration of the graft function
appears to be important, and it is possible that early correction
of low Hb levels might slow down this process.
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